Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Inventory (2019 - 2021)

VYNE Therapeutics (VYNE) has disclosed Inventory for 3 consecutive years, with $7.3 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Inventory fell 1.53% year-over-year to $7.3 million, compared with a TTM value of $7.3 million through Dec 2021, down 1.53%, and an annual FY2021 reading of $7.3 million, down 1.53% over the prior year.
  • Inventory was $7.3 million for Q4 2021 at VYNE Therapeutics, down from $8.1 million in the prior quarter.
  • Across five years, Inventory topped out at $8.3 million in Q2 2021 and bottomed at $1.4 million in Q4 2019.
  • Average Inventory over 3 years is $6.2 million, with a median of $7.3 million recorded in 2021.
  • The sharpest move saw Inventory soared 446.02% in 2020, then fell 1.53% in 2021.
  • Year by year, Inventory stood at $1.4 million in 2019, then skyrocketed by 446.02% to $7.4 million in 2020, then fell by 1.53% to $7.3 million in 2021.
  • Business Quant data shows Inventory for VYNE at $7.3 million in Q4 2021, $8.1 million in Q3 2021, and $8.3 million in Q2 2021.